Saint-Julien adds bioconjugation and development capabilities that complement HPAPI and
payload expertise in Rodano, while the Concord, Ohio site doubles production capacity.
Developing antibody-drug conjugates (ADCs) calls for expertise across multiple technologies, from monoclonal antibodies (mAbs) and bioconjugation to highly potent payloads. Olon is expanding its ADC platform at Saint-Julien, France, while strengthening its links with its Rodano, Italy site. Customers gain access to complementary capabilities within a single network as their projects move from development to commercial manufacturing.
At Saint-Julien, Olon is adding a dedicated Bio-development Unit for mAbs and ADCs, together with new research and process development laboratories and increased bioconjugation and manufacturing capacity. The expansion is designed to support customers through process optimisation, scale-up and commercial manufacturing. Rodano contributes complementary expertise in highly potent active pharmaceutical ingredients (HPAPIs) and payloads, with handling capabilities up to OEB 6. Together, the two sites offer connected capabilities for the development and manufacture of complex ADCs. “Customers developing ADCs need more than individual capabilities. They need a partner that can connect them as a programme progresses,” said Maurizio Sartorato, Vice President Biotech at Olon. “By expanding Saint-Julien and linking its biologics and bioconjugation
expertise with Rodano’s work on HPAPIs and payloads, we can offer greater continuity from
development into manufacturing.”
A new development centre combining ADC and mammalian cell development is planned to open by the end of 2026. Further investments to expand ADC manufacturing capacity are expected to be completed in early 2027, creating a scalable platform to support both development and commercial production.
Alongside its ADC activities, Olon has completed the expansion of its Concord, Ohio site, which focuses on chemical manufacturing. The expansion doubles the site’s production capacity and adds commercial-scale manufacturing to its existing chemical synthesis, process development and early-stage production capabilities. Recent FDA inspections at the site were completed with no observations. The site is operational, with customer projects already under way and serves as a US manufacturing hub for companies looking to establish or scale production in the country.
“Whether a customer is advancing a complex biologic or looking to establish production in the United States, the question is the same: can their manufacturing partner support the next stage of the programme?” said Paolo Tubertini, CEO of Olon. “We invest where greater integration can make a meaningful difference for our customers. By bringing complementary scientific expertise, capacity and infrastructure together across our network, we can support customers as their needs evolve, from development through to commercialisation and,
ultimately, to patients.”
About Olon
Olon is an Italian company specialising in the development and production of active pharmaceutical ingredients
(APIs), combining expertise in chemical synthesis and biological processes. Headquartered in Rodano (Milan,
Italy), Olon operates 14 manufacturing sites and 14 R&D centers worldwide, with over 2,800 employees. With
decades of experience, the company provides end-to-end support, from early development to commercial
manufacturing, while maintaining a strong commitment to innovation, sustainability, and quality.
For more information, visit www.olonspa.com.



















